Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P08237
UPID:
PFKAM_HUMAN
Alternative names:
6-phosphofructokinase type A; Phosphofructo-1-kinase isozyme A; Phosphohexokinase
Alternative UPACC:
P08237; J3KNX3; Q16814; Q16815; Q6ZTT1
Background:
ATP-dependent 6-phosphofructokinase, muscle type, also known as 6-phosphofructokinase type A, plays a pivotal role in glycolysis. It catalyzes the transformation of D-fructose 6-phosphate into fructose 1,6-bisphosphate, a key step in the metabolic pathway that generates energy from glucose.
Therapeutic significance:
This enzyme's malfunction is linked to Glycogen storage disease 7, characterized by exercise intolerance, muscle cramping, and myoglobinuria. Understanding its function could lead to novel treatments for this metabolic disorder.